easd
Entity, reached from Hormuz.
- Evidence
- 37 documents · 13 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 23 Sept 2026, last seen 6 Oct 2026
- Measured
- 0% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Medical Device Network · 2026-10-06 · EASD 2026: MiniMed touts Smart MDI system alert response benefits in type 1 diabetes patients (opens the source in a new tab)
- PR Newswire · 2026-10-04 · SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026 (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-03 · EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-03 · EASD 2026: GLP-1 and SGLT2 treatment lowers mortality in heart failure patients (opens the source in a new tab)
- PR Newswire · 2026-10-02 · Úbytek hmotnosti o 19,3 % ve 48. týdnu: Na EASD byla představena studie fáze III zaměřené na regulaci tělesné hmotnosti s olatorepatidem od Hansoh (opens the source in a new tab)
- European Medical Journal · 2026-10-02 · Impaired Insulin Sensitivity Linked to Lung Function: EASD 2026 (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-02 · EASD 2026: Semaglutide shows promise in treating obesity-related heart failure (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-02 · EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-02 · EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-02 · EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability (opens the source in a new tab)
2 more on file, counted in the evidence above.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with european association (22 documents)seen together
- co-mentioned with glp-1 (22 documents)seen together
- co-mentioned with annual meeting (19 documents)seen together
- co-mentioned with italy (18 documents)seen together
- co-mentioned with clinical trials (13 documents)seen together
- co-mentioned with clinical trial (11 documents)seen together
- co-mentioned with unlock free access (9 documents)seen together
- co-mentioned with drug development (9 documents)seen together
- co-mentioned with hba1c (8 documents)seen together